Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Windtree’s Phase II Success In Cardiogenic Shock Could Lead To Heart Failure Opportunity

Executive Summary

On the way to seeking approval for istaroxime in acute heart failure, Windtree became convinced that early cardiogenic shock could be a good get-to-market strategy for its blood pressure-improving drug.

You may also be interested in...



La Jolla’s Giapreza: Emergency Use Requests Sped US FDA Approval For Septic Shock

After publication of ATHOS-3 study results, agency received several requests from medical community for emergency use in hospitalized patients with shock and hypotension unresponsive to available therapy, spurring FDA to take an approval action two months ahead of user fee goal date.

Asia Deal Watch: Taiho Brings Cullinan Pearl Back In House

Taiho will pay Cullinan Oncology up to $405m for their joint venture and lead candidate for a form of lung cancer. Plus deals involving Zhaoke/Visus, AnGes/Eiger, Juniper/Helsinn, Peak Bio and more.

From Regulatory Affairs To R&D, Sanofi’s Mura Has Broad Strategic View

From a legal family in her native Brazil, Raquel Mura built on her passion for science to work in consumer health care, nutritionals and pharmaceuticals, rising to an R&D leadership position at Sanofi.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146256

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel